Navigation Links
NIMOTUZUMAB CLINICAL DATA PRESENTED AT ASCO ANNUAL MEETING
Date:6/3/2008

overall survival was 9.7 months and that 12 of the 41 evaluable patients are currently alive. No incidences of rash were noted and results were reported to be comparable to intense chemotherapy and radiotherapy. Quality of life was reported as excellent when compared with intensive chemotherapy. Current and planned studies will expand the use of nimotuzumab from the pediatric population to adults with high grade brain tumors.

"Pharmacodynamic (PD) study of Nimotuzumab, an anti epidermal growth

factor receptor (EGFR) monoclonal antibody (MAb), in patients with

unresectable squamous cell carcinoma of the head and neck (SCCHN): A

SENDO Foundation study" (Abstract number 6070): Ten patients with advanced SCCHN, unsuitable for chemo-radiotherapy, were enrolled in a single center phase Ib clinical trial, where they received eight weekly infusions of nimotuzumab at two dose levels: 200mg and 400mg. Paired biopsies were taken from skin and primary tumors, before and 1 week after first infusion.

Nimotuzumab was well tolerated and there was no evidence of skin rash in any of the treated patients. Objective Response was achieved in 80% of patients (2 Complete Responses, 6 Partial Responses) and median survival time was 7.2 months. Results also demonstrated that after a short period of exposure, nimotuzumab as a single agent inhibited EGFR phosphorylation and this was accompanied by a trend towards molecular downstream effects consistent with the expected biological effects of EGFR targeting. The absence of inflammatory skin reaction might be linked to the lack of skin toxicity by the drug.

In addition, YM BioSciences presented data, described in a separate press release issued today by the Company, based on the following poster:
"Preliminary results of an escalating dose phase I clinical trial of the

anti-EGFR monoclonal antibody nimotuzumab in combination with external

radiotherapy in patients diagnosed
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. YM BIOSCIENCES REPORTS NIMOTUZUMAB NSCLC CLINICAL DATA AT ASCO ANNUAL MEETING
2. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB COLORECTAL CANCER TRIAL FIRST COHORT IS CLOSED TO ACCRUAL
3. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
4. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
5. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
6. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
7. Angiotech announces completion of Bio-Seal(TM) clinical trial enrolment
8. DermTech Names Herbert A. Fritsche, Ph.D., Chief of Clinical Chemistry at M.D. Anderson Cancer Center to Companys Scientific Advisory Board
9. Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting
10. Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation
11. Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/11/2014)... Fla. , Sept. 11, 2014 /PRNewswire/ ... anti-infective pharmaceuticals, announced today that the United ... a ,Notice of Allowance, for patent application ... Uses,.  The ,486 patent application relates to ... through gene-silencing and can be designed to ...
(Date:9/11/2014)... Entries are now being accepted for the annual ... colleagues within the healthcare industry select who wins. Now in ... best in healthcare creative campaigns. The awards are unique in ... and wellness industry. All entries are placed online, and healthcare ... each category. , “No one knows what it takes ...
(Date:9/11/2014)... September 11, 2014 Genera Energy ... innovation and supply chain advancements, recently introduced its newest ... BIN-SPEC delivers a consistent biomass product to a customer’s ... a lower cost. , “After producing and harvesting ... place to convert a field crop into a uniform ...
(Date:9/11/2014)... 11, 2014 Central Florida board-certified veterinary ... partnerships with several Brevard County animal hospitals to bring ... been working in the area since January 2006, credentialed ... 2008, and is happy to now offer his expertise ... Christiansen has used stem cell therapy with Vet-Stem, Inc. ...
Breaking Biology Technology:Lakewood-Amedex Receives Notice Of Allowance From The United States Patent and Trademark Office (USPTO) For A New Patent Covering Its nanoRNA Gene-Silencing Technology 2Lakewood-Amedex Receives Notice Of Allowance From The United States Patent and Trademark Office (USPTO) For A New Patent Covering Its nanoRNA Gene-Silencing Technology 3PM360 Now Accepting Entries for 2014 Pharma Choice Awards 2Genera Energy’s BIN-SPEC™ Reduces Biomass Feedstock Variability 2Genera Energy’s BIN-SPEC™ Reduces Biomass Feedstock Variability 3Dr. Jeff Christiansen is Now Offering Stem Cell Therapy for Pets at Five Brevard County Animal Hospitals and Beyond 2Dr. Jeff Christiansen is Now Offering Stem Cell Therapy for Pets at Five Brevard County Animal Hospitals and Beyond 3
... ON - Clean solutions to human energy demands are essential ... of energy at our disposal, we have yet to learn ... According to University of Toronto chemistry professor Greg Scholes, the ... in nature. "Solar fuel production often starts with the ...
... Citizens Bank today announced that it is providing $70 ... The Wistar Institute that includes a new seven-story 89,700-square-foot ... and Spruce streets in University City. The ... basic biomedical research, particularly cancer research and vaccine development ...
... first laser in 1960 scientists discovered that shining a beam ... specifically, it produced light of exactly twice the frequency of ... The green laser pointers in use today to illustrate ... beautiful emerald beam is no easy feat. The green light ...
Cached Biology Technology:Nature offers key lessons on harvesting solar power, says U of T chemistry professor 2Citizens Bank Provides $70 Million in Financing Toward $100 Million Expansion of The Wistar Institute 2Stanford engineers create nanoscale nonlinear light source 2Stanford engineers create nanoscale nonlinear light source 3Stanford engineers create nanoscale nonlinear light source 4
(Date:9/12/2014)... and condition of extraction of type I collagen fibrils, ... of their circular circular cross sections stay distributed in ... the most part of them. Jean Charvolin and Jean-Francois ... Paris-Sud University propose therefore that, once the growth of ... their lateral size be limited by internal physical stresses ...
(Date:9/12/2014)... to dealing with climate change: Advances in hydraulic ... unreachable oil and natural gas within humanity,s grasp. ... from "fracking," which requires blasting huge amounts of ... formations, are the subject of new research that ... survey covers not only greenhouse gas impacts but ...
(Date:9/12/2014)... and POINT ROBERTS, Washington , ... Investorideas.com ( http://www.investorideas.com ) a global news source covering leading ... and experts on the September 9 th launch of ... of Goode Intelligence, Janice Kephart , founder of the ... Pereira of NXT-ID, Inc, (NASDAQ: NXTD ) ...
Breaking Biology News(10 mins):Conjecture on the lateral growth of Type I collagen fibrils 2Stanford-led study assesses the environmental costs and benefits of fracking 2Stanford-led study assesses the environmental costs and benefits of fracking 3Stanford-led study assesses the environmental costs and benefits of fracking 4Biometric Experts Comment on Launch of Apple Pay Smart Wallet Payment Service 2Biometric Experts Comment on Launch of Apple Pay Smart Wallet Payment Service 3Biometric Experts Comment on Launch of Apple Pay Smart Wallet Payment Service 4Biometric Experts Comment on Launch of Apple Pay Smart Wallet Payment Service 5
... cure, is a common expression, but what happens if preventative ... women are going out of their way not to be ... recent paper by Larsson et al. in AIDS ... and cost-effectively prevented using a short course of antiretroviral therapy. ...
... Researchers from Stony Brook University Medical Center in New ... genuine ancient human species and not a descendant of healthy ... remains of a well-preserved female specimen, researchers determined the "hobbit" ... version of modern humans. Details of the study appear ...
... In an advance with overtones of Star Trek phasers and ... of an internal on-off "switch" that paralyzes animals when exposed ... even when the light is turned off. When exposed to ... study appears in the Journal of the American Chemical ...
Cached Biology News:'Hobbits' are a new human species -- according to the statistical analysis of fossils 2
Collected from calves that are 10 days old or less. Sterile, cell culture tested, US Origin...
... Whole Genome Amplification Kit utilizes a ... of genomic DNA and conversion of ... library molecules flanked by universal priming ... amplification of the library molecules using ...
... ultra-pure recombinant thermostable DNA polymerase obtained by ... polymerase gene in E. coli, Concentration: 5U/ul, ... Thermo Fisher Scientific, the world leader in ... to make the world healthier, cleaner and ...
... Analysis of large numbers of samples may ... system which requires minimum operator attention. ... PowerStream software and interface CE 4900. The ... operates in Windows XP and Windows 98 and ...
Biology Products: